---
figid: PMC9413091__pharmaceuticals-15-01014-g003
pmcid: PMC9413091
image_filename: pharmaceuticals-15-01014-g003.jpg
figure_link: /pmc/articles/PMC9413091/figure/pharmaceuticals-15-01014-f003/
number: Figure 3
figure_title: ''
caption: Molecular docking of galangin with core targets. (A) Galangin binds to NFE2L2/Nrf2
  protein (7K29) via the active residues VAL-420 and VAL-514. (B) Galangin binds to
  HMOX-1/HO-1 protein (6EHA). (C) Galangin binds to Keap1 protein (1ZGK) via the active
  residues VAL-418, VAL-606, GLY-367, and LEU-365.
article_title: Galangin Exhibits Neuroprotective Effects in 6-OHDA-Induced Models
  of Parkinson’s Disease via the Nrf2/Keap1 Pathway.
citation: Qiu-Xu Chen, et al. Pharmaceuticals (Basel). 2022 Aug;15(8):1014.
year: '2022'

doi: 10.3390/ph15081014
journal_title: Pharmaceuticals
journal_nlm_ta: Pharmaceuticals (Basel)
publisher_name: MDPI

keywords:
- galangin
- 6-OHDA
- Parkinson’s disease
- Keap1/Nrf2
- network pharmacology

---
